Skip to main content
Glama

Ecfr

by io.github.pipeworx-io

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.5/5.0
Behavior4/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations indicate read-only, idempotent, open-world, and non-destructive behavior. The description adds details on data sources (SEC EDGAR/XBRL for companies, FAERS for drugs), fiscal year handling, sorted results by primary metric, and citation URIs, providing valuable context beyond annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with example queries, then provides behavioral details and output information. Every sentence adds value, and there is no wasted text. It is efficiently structured and easy to parse.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Despite no output schema, the description covers what data is returned for each type, sorted order, and citation URIs. For a comparison tool of moderate complexity, this is sufficient for an AI agent to correctly invoke the tool.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so baseline is 3. The description adds semantic value by specifying that values should be tickers/CIKs for companies and drug names for drugs, and that max is 5 items. This clarifies usage beyond the schema's generic descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool performs side-by-side comparisons of 2-5 companies or drugs in one parallel call. Example queries are provided, and it distinguishes itself from sibling tools like entity_profile and sequential lookups.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says to prefer this tool over sequential single-pack lookups when comparing entities, and explains when to use company vs drug type. However, it does not explicitly mention scenarios where this tool should not be used, though it's generally clear.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Ecfr toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.7/5.0
Disambiguation2/5

Multiple tools have heavily overlapping purposes: ask_pipeworx, ask_pipeworx_beta, and ask_pipeworx_grounded are near-duplicates (beta is currently identical), and ai_visibility_check vs scan_competitor_ai_presence plus deep_research vs ask_pipeworx create real selection ambiguity. Some clusters like the memory trio and CFR read tools are distinct, but the overall set is confusing.

Naming Consistency3/5

Most tools use snake_case and many follow a verb_noun pattern (search_regulations, generate_llms_txt, validate_claim), but noun-first names (entity_profile, title_structure, ai_visibility_check) and prefix families (polymarket_*, pipeworx_*) break the pattern. The conventions are mixed but still readable and mostly predictable.

Tool Count2/5

35 tools is heavy for any single server, and the bulk of them (Polymarket betting, memory, AI visibility, npm scanning, subscriptions) are unrelated to the server's 'Ecfr' name, which suggests a narrow regulatory focus. This is a kitchen-sink scope, making the count feel bloated rather than well-scoped.

Completeness3/5

The eCFR-specific surface is thin — list_titles, search_regulations, get_section_text, and title_structure cover basic read/search but lack version history, update tracking, or agency-level navigation. Other mini-domains (data lookup, polymarket, subscriptions, memory) are individually fairly complete, but the absence of a unified purpose leaves clear gaps overall.

Resources